Collectively, these observations argue that the prognostic and therapeutic meaning of “high autophagy/beclin-1” versus “low autophagy/beclin-1” should be evaluated with explicit consideration of subtype (IDH/G-CIMP; proneural vs. mesenchymal) and treatment context (MGMT/TMZ exposure), rather than as a single unified GBM biomarker. The gene discussed is IDH1; the disease is glioblastoma.